This research is Trending!
Randomized, Placebo-Controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina
Key result
In patients with single-vessel CTO, CTO PCI improved the angina symptom score compared with a placebo procedure (OR 4.38; 95% CrI 1.57-12.69; Pr[Benefit]=0.996).
Why the trial?
The ORBITA-CTO trial was conducted to address the lack of blinded randomized evidence on whether percutaneous coronary intervention (PCI) for coronary chronic total occlusion (CTO) improves symptoms and quality of life in patients with angina attributable to a single-vessel CTO.
Does CTO PCI improve angina symptoms in patients with stable angina attributable to a single-vessel CTO compared to a placebo procedure?
Population
50 patients with angina attributable to a single-vessel chronic total occlusion, without bystander coronary…
Comparison
Percutaneous coronary intervention for coronary… vs Placebo procedure. Antianginal medications were…
Design
RCT, Randomized, Blinded; maintained using auditory isolation and deep…
Follow-up
6 months
Authors
Discussion
Key questions
No takes yet. Share an insight, caveat, or question.
Where experts stand
Experts read ORBITA-CTO as the first placebo-controlled proof that CTO PCI genuinely relieves angina, though they flag questions about how broadly the results apply beyond the trial's highly selected patients and operators.
Interventional cardiologists welcome this as landmark evidence that CTO PCI produces real, not placebo-driven, symptom relief. There is broad agreement the trial design was rigorous, but some experts caution that the tightly selected patient population and specialist operators may limit generalizability. The live question is which patients and clinical settings will see the same benefit.
Agreement
Multiple experts agree that ORBITA-CTO fills a critical evidence gap by providing the first blinded, placebo-controlled demonstration that CTO PCI truly improves angina symptoms beyond placebo effect.
4 clinicians say this directly
Still unclear
Experts note that the trial enrolled a narrow group of patients with single-vessel CTOs treated by specialist operators, leaving open how well the results generalize to broader CTO populations and less experienced centers. Determining which patients benefit most from the procedure remains the next challenge.
Key expert perspectives
SWSergio WaxmanInterventional cardiologist, RWJ Barnabas HealthEndpoint critiqueMar 31
Generalizability is the main concern given the highly selected patients and operators
Waxman praised the trial design as meticulous but cautioned that enrolling only patients with single-vessel CTOs and no other significant coronary disease, treated by a selected group of operators, raises questions about how broadly the results can be applied.
Distilled from their postOriginal post
ZAZiad A. AliInterventional cardiologist, institution not specifiedContextMar 31
This evidence is invaluable for a field that relied on technical success as a surrogate for clinical effect
Ali called the trial invaluable for moving CTO PCI beyond technical accomplishment toward proven clinical benefit. He identified the next challenge as determining when and for whom the procedure works best.
Distilled from their postOriginal post
JDJohn DaviesInterventional cardiologist, Essex Cardiothoracic CentreResults readoutMar 31
CTO PCI delivers immediate, sustained, and consistent angina relief even against placebo
Davies, as a trial investigator, emphasized that no prior CTO study had compared the procedure to a placebo, making this the first to show the benefit is real and not driven by patient expectations. He said the results support symptom-driven PCI in carefully selected patients at centers with specialist CTO operators.
Implication
Supports CTO PCI for symptom relief in single-vessel CTO; confirms benefit in first placebo-controlled RCT and strengthens Class IIa guidance.
Key Points
- This study aims to evaluate the efficacy of chronic total occlusion percutaneous coronary intervention in improving symptoms of stable angina.
- Multicenter, randomized, blinded trial comparing CTO PCI with placebo procedure.
- Patients with single-vessel CTO and angina were included and randomized to CTO PCI or placebo after angiography.
- Symptom assessment continued through the ORBITA app over a 6-month follow-up.
- CTO PCI led to significant improvement in angina symptom score (OR: 4.38; 95% CrI: 1.57-12.69; Pr{Benefit} = 0.996).
- There was a clear reduction in angina episodes resulting in an additional 30.6 days free of angina (95% CrI: 11.1-50.7; Pr[Benefit] >0.999).
- Improvements observed in multiple quality of life metrics and maintained blinding throughout the trial.
Study Design
Type
RCT (n=50)
Blinding
Blinded
Randomization
Randomized
Multicenter
Yes
Structured PICO
Does CTO PCI improve angina symptoms in patients with stable angina attributable to a single-vessel CTO compared to a placebo procedure?
P
Population
50 patients with angina attributable to a single-vessel chronic total occlusion (CTO), without bystander coronary disease.
I
Intervention
Percutaneous coronary intervention for coronary chronic total occlusion (CTO PCI). Antianginal medications were stopped at randomization and reintroduced on a patient-initiated protocol.
C
Comparator
Placebo procedure. Antianginal medications were stopped at randomization and reintroduced on a patient-initiated protocol.
O
Outcome
Angina symptom score (an ordinal scale combining the daily symptom burden assessed by the ORBITA app, antianginal use, and over-ride events) at 6-month follow-up.patient reported
Main Result
Effect estimate: OR 4.38 (95% CI 1.57-12.69)
p-value: Pr[Benefit] = 0.996
In the first placebo-controlled trial of CTO PCI, the procedure significantly improved angina symptoms and quality of life in patients with single-vessel CTO.
Cite This Study
Khan et al. (2026) conducted an RCT in Stable angina with single-vessel chronic total occlusion (n=50). Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI) vs. Placebo procedure was evaluated on Angina symptom score (ordinal scale combining daily symptom burden, antianginal use, and over-ride events) (OR 4.38, 95% CI 1.57-12.69, p=Pr[Benefit] = 0.996). In patients with single-vessel CTO, CTO PCI improved the angina symptom score compared with a placebo procedure (OR 4.38; 95% CrI 1.57-12.69; Pr[Benefit]=0.996).